[2] PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. Retrieved December 9, 2019, from https://www.blueprintmedicines.com/wp-content/uploads/2019/12/Blueprint-Medicines-ASH-2019-Avapritinib-SM-Poster.pdf
原标题:ASH | 精准抗癌疗法2期数据积极,治疗罕见免疫疾病
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。▽关注【药明康德】微信公众号